Ondo InsurTech Reports 115% US Revenue Growth but Faces Immediate Funding Need

Ondo InsurTech’s US surge is real – but cash is tight and funding is coming

Ondo InsurTech’s latest trading update is a classic two-hander: strong operational progress – especially in the United States – paired with a clear and immediate need for extra cash. For the year to 31 March 2026, group revenue rose 19% to £4.6 million, while US revenue leapt 115% to £2.3 million. Recurring revenue did the heavy lifting, up 50% to £3.8 million.

Set against that, the company ended the year with £1.1 million in cash (down from £4.0 million), is seeing some partner orders slip or turn uncertain, and is now actively exploring financing options – including a potential equity raise. Here’s what stood out and why it matters for shareholders.

Key numbers from the trading update

Metric	FY26	FY25	Comment
Group revenue	£4.6 million	£3.9 million	Up 19%
Recurring revenue	£3.8 million	£2.5 million	Up 50%
One-off device fee revenue	£0.8 million	£1.3 million	Down 39%
USA revenue	£2.3 million	£1.1 million	Up 115% (49% of group)
Annualised Contracted Recurring Revenue (ACRR)	£6.8 million	£5.9 million	Increased, driven by not-yet-deployed programmes
Cash at 31 March	£1.1 million	£4.0 million	Lower, funding now required
Registered customers	209,812	150,934	Up 39%
USA customers	57,408	26,831	Up 114% across 26 states
In-home repairs (USA)	3,070	1,379	Up 123%
Net Promoter Score (NPS)	+88	+79	Service quality improved with scale

US growth and scaling proof points

The US is now Ondo’s largest market by revenue, customers and contracted recurring revenue. The company ran LeakBot programmes with 10 insurance partners across 26 states, landing new or expanded contracts with Nationwide (the third consecutive and largest-to-date order), Westfield Insurance, Indiana Farm Bureau Insurance and Selective Insurance, plus new launches with Hanover and Liberty Mutual.

Operationally, the US engine is humming: in-home repairs more than doubled to 3,070 and documented claims savings for partners rose more than fourfold. Net Promoter Score improved to +88, which is unusually high and suggests the customer experience is holding up even as volumes scale.

Revenue mix is shifting to recurring

Recurring revenue climbed to £3.8 million, while one-off device fees fell to £0.8 million. That mix shift tends to be a positive for visibility and valuation over time, because recurring revenue is more predictable than upfront hardware sales. The increase in ACRR to £6.8 million – which includes contracted but not-yet-activated devices expected to go live within 18 months (based on a 70% activation assumption) – underpins that visibility.

One note of caution: contracted revenue only converts to cash once devices are deployed and paying. Any delay in partner re-orders or rollouts can pinch cash – which is exactly what management has flagged.

Europe not standing still: NFU Mutual and Alm. Brand

In the UK, NFU Mutual became the largest partner and the first to adopt a recurring pricing model. In the Nordics, Alm. Brand Group committed to a minimum 15,000 devices across three brands, with deployment starting in March 2026. These are useful diversification points alongside the US push.

Cash position and immediate funding need

Ondo ended the year with £1.1 million of cash. Management says some partner orders are now tracking later than anticipated or are not certain to be received, even as others look set to step up. The combination leaves an immediate short-term funding requirement.

To ease near-term pressure, Ondo has tweaked the terms of the vendor loan notes held by its largest shareholder, HomeServe Assistance Limited. The changes help liquidity but at a higher cost of debt:

• Interest roll-up extended: first cash interest payment now due on 30 December 2026 (was 30 June 2026).
• Repayment deferral: warrant-related repayments in H2 2026 split into two instalments due 30 September and 31 December 2026.
• Interest rate step-up: 13% from 31 March 2026 (was 12%); 15% from 31 March 2027 (was 14%).
• Warrant proceeds: at least 40% of any further warrant exercise proceeds will go to repay the loan notes.

There are 2,411,663 warrants outstanding with an exercise price of 20 pence, representing up to approximately £482,333 of potential cash proceeds if exercised by 22 May 2026. Whether holders exercise is not disclosed.

Crucially, these amendments alone do not fix the short-term funding gap. The Board is exploring a range of other financing options, including a possible equity fundraising. No size, price or structure has been disclosed.

Why this matters for Ondo shareholders

The bull case

• Real US traction: 115% revenue growth, broader partner base, and strong customer satisfaction at scale.
• Recurring revenue momentum: 50% growth and ACRR up to £6.8 million supports improving visibility.
• Operational proof: in-home repairs up 123% and documented claims savings up more than fourfold strengthens the insurer value proposition.

The bear case

• Funding risk now front and centre: £1.1 million year-end cash and delayed/uncertain re-orders mean Ondo needs fresh capital quickly.
• Potential dilution: an equity raise is on the table; terms are not disclosed.
• Higher cost of debt: loan note interest stepping up to 13% and then 15% increases future finance costs.

Profitability, operating loss and cash burn are not disclosed in this update. Investors will want those details at results time to gauge runway and the path to break-even.

What to watch next

• Financing announcement: timing, structure and quantum – including any equity component and pricing – not disclosed yet.
• Warrants expiring 22 May 2026: up to c.£482,333 of potential cash if exercised.
• Deployment pace: conversion of contracted programmes into active, paying devices to support ACRR realisation.
• Full-year results: expected on Wednesday, 29 July 2026, with fuller financials and outlook detail.

Josh’s take

Strategically, this is the update Ondo needed on US traction: more partners, more states, bigger orders, happier customers. Financially, it’s the update no small-cap loves to give: immediate funding required due to order timing and a low cash balance.

If management can land financing on acceptable terms and keep deployment momentum, the growing base of recurring revenue and contracted programmes could set up a stronger FY27. Until then, expect the shares to trade on funding headlines and execution on partner rollouts. High potential, higher near-term risk – classic growth-stage territory.